In a report released today, Marc Goodman from SVB Securities maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $27.00. The company's shares closed last Friday at $15.74. According to TipRanks.com, Goodman is a 2-star analyst with an average return of 0.2% and a 46.8% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Opthea Limited Sponsored ADR, and Amylyx Pharmaceuticals Inc. ACADIA Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $22.64, representing a 45.7% upside.
https://www.tipranks.com/news/blurbs/acadia-pharmaceuticals-acad-gets-a-buy-rating-from-svb-securities?utm_source=advfn.com&utm_medium=referral
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.